Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia

Hematology

Volumn 18, Issue 4, 2013, Pages 191-197

  Liao, Rongxia ^a   Xu, Yanmei ^a   Chen, Min ^a   Chen, Xiewan ^a   Zhan, Xiaoqing ^a   Sun, Jianguo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloblastic leukemia; Gene expression regulation; Hematopoietic stem cell damage; MicroRNAs; Myelodysplastic syndrome

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; MICRORNA; MICRORNA 125A; MICRORNA 125B; MICRORNA 126; MICRORNA 142; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 181; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 29A; MICRORNA 33; MICRORNA 378; MICRORNA 632; MICRORNA 636; MICRORNA 720; MICRORNA 99B; PLERIXAFOR; PROTEIN BCL 2; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR RUNX1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BLEEDING; CANCER PROGNOSIS; CELL DAMAGE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DEATH; DNA MICROARRAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION; MALIGNANT TRANSFORMATION; MUTATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; RNA TRANSLATION; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MYELODYSPLASTIC SYNDROMES;

EID: 84880008943     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000053     Document Type: Review

References (53)

1. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, et al. Patients with del(5q) MDS who failto achieve sustained erythroid or cytogenetic remission after treatment withlenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365-74.
2. Hatfield S, Ruohola-Baker H. microRNA and stem cell function. Cell Tissue Res. 2008;331(1):57-66.
3. Shcherbata HR, Hatfield S, Ward EJ, Reynolds S, Fischer KA, Ruohola-Baker H. The MicroRNA pathway plays a regulatory role in stem cell division. Cell Cycle. 2006;5(2):172-5.
4. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA. 2005;102(50):18081-6.
5. Georgantas RW, 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA. 2007;104(8):2750-5.
6. Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D, et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci USA. 2010;107(35):15443-8.
7. Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H, et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med. 2008;22(6):39.
8. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654): 83-6.
9. Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem. 2008;104(3):805-17.
10. Salvucci O, Jiang K, Gasperini P, Maric D, Zhu J, Sakakibara S, et al. MicroRNA126 contributes to G-CSF-induced hematopoietic progenitor cell mobilization by reducing VCAM-1 expression. Haematologica. 2012;97(6):818-26.
11. Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E, et al. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood. 2012;119(2):377-87.
12. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA. 2010;107(32):14229-34.
13. + hematopoietic stem and progenitor cells. Stem Cells. 2011;29(5):847-57.
14. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol. 2011;39(2):167-178, e4.
15. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, et al. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle. 2010; 9(16):3277-85.
16. Risitano AM, Maciejewski JP, Selleri C, Rotoli B. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. Curr Stem Cell Res Ther. 2007;2(1):39-52.
17. Nilsson L, Edén P, Olsson E, Månsson R, Astrand-Grundström I, Strömbeck B, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007;110(8):3005-14.
18. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319(5861):336-9.
19. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010;85(5):331-9.
20. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205(3):585-94.
21. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944-9.
22. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006; 66(24):11590-3.
23. + cells. Blood. 2007;109(10):4399-4405.
24. Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-McIver A, Young BD. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia. 2007;21(5):912-6.
25. Hussein K, Büsche G, Muth M, Göhring G, Kreipe H, Bock O. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol. 2011;90(3):307-13.
26. Larson RA. Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia. Chem Biol Interact. 2010;184(1-2):21-5.
27. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA. 2010;107(32):14235-40.
28. Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA. 2012; 109(11):4233-8.
29. Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL, et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012;119(21):4992-5004
30. Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C, et al. Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol. 2010;92(1):129-35.
31. Beck D, Ayers S, Wen J, Brandl MB, Pham TD, Webb P, et al. Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. BMC Med Genomics. 2011;4:19.
32. + cells of 5q-syndrome. J Hematol Oncol. 2011;6(4):1.
33. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16(1):49-58.
34. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q-syndrome. Blood. 2011; 118(17):4666-73.
35. Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M, Garcia-Manero G, et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood. 2011;118(2): 413-5.
36. Erdogan B, Facey C, Qualtieri J, Tedesco J, Rinker E, Isett RB, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol. 2011;39(9):915-26, e2.
37. Borze I, Scheinin I, Siitonen S, Elonen E, Juvonen E, Knuutila S. miRNA expression profiles in myelodysplastic syndromes reveal Epstein-Barr virus miR-BART13 dysregulation. Leuk Lymphoma. 2011;52(8):1567-73.
38. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, et al. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012;31(37):4085-94.
39. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F, et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA. 2010;107(21):9783-8.
40. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011; 153(1):24-32.
41. Mano H. DNA micro-array analysis of myelodysplastic syndrome. Leuk Lymphoma. 2006;47(1):9-14.
42. Mihara K, Takihara Y, Kimura A. Genetic and epigenetic alterations in myelodysplastic syndrome. Cytogenet Genome Res. 2007;118(2-4):297-303.
43. Roela RA, Carraro DM, Brentani HP, Kaiano JH, Simão DF, Guarnieiro R, et al. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. Leuk Res. 2007;31(5):579-89.
44. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol. 2008;142(5):695-708.
45. Mills KI, Kohlmann A, Williams PM, Wieczorek L, Liu WM, Li R, et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood. 2009;114(5):1063-72.
46. Mahadevan D, DiMento J, Croce KD, Riley C, George B, Fuchs D, et al. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. Am J Hematol. 2006;81(10):779-86.
47. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008; 205(11):2499-2506.
48. Slape C, Hartung H, Lin YW, Bies J, Wolff L, Aplan PD. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res. 2007;67(11):5148-55.
49. Enomoto Y, Kitaura J, Shimanuki M, Kato N, Nishimura K, Takahashi M, et al. MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m)-induced myeloid leukemia. Int J Hematol. 2012;96(3):334-41.
50. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet. 2011;19(3):313-9.
51. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma. 2009;50(11):1854-9.
52. Hussein K, Theophile K, Büsche G, Schlegelberger B, Göhring G, Kreipe H, et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res. 2010;34(3):328-34.
53. Vigna E, Recchia AG, Madeo A, Gentile M, Bossio S, Mazzone C, et al. Epigenetic regulation in myelodysplastic syndromes: implications for therapy. Expert Opin Investig Drugs. 2011; 20(4):465-93.